NRAS and melanoma: The inactivation of p16CDKN2A is due to either genetic (mutations, deletions) or epigenetic (promoter methylation) mechanisms, whereas the amplification of CCND1 is particularly frequent in melanomas negative for BRAF/NRAS mutations, in chronically sun-exposed skin areas [53].